Please Wait
Applying Filters...
menu
    • menu
    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Jai Radhe Sales is your partner for all your sourcing needs.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Nicotinamide Riboside

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    MARKET PLACE

    PharmaCompass
    $ API Ref.Price (USD/KG) : 914Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Niagen® improves mobility in PAD per Phase II study.
    Niagen® improves mobility in PAD per Phase II study.

    24 Jun 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240624062781/en

    BUSINESSWIRE
    24 Jun 2024
    Share Share
    A Milestone Clinical Study Reveals that Elevating Nicotinamide Adenine Dinucleotide (NAD+) with Nicotinamide Riboside (NR) Supplementation Effectively Reduces Inflammation in Both Healthy Subjects and Immune Cells Derived from Psoriasis Patients
    A Milestone Clinical Study Reveals that Elevating Nicotinamide Adenine Dinucleotide (NAD+) with Nicotinamide Riboside (NR) Supplementation Effectively Reduces Inflammation in Both Healthy Subjects and Immune Cells Derived from Psoriasis Patients

    02 Oct 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20231002427548/en

    BUSINESSWIRE
    02 Oct 2023
    Share Share
    Thorne Research, Inc. Loses Patent Challenge Decision
    Thorne Research, Inc. Loses Patent Challenge Decision

    15 Aug 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20220815005235/en

    BUSINESSWIRE
    15 Aug 2022
    Share Share
    ChromaDex Shares Findings from First-Ever Peer-Reviewed Published Clinical Study
    ChromaDex Shares Findings from First-Ever Peer-Reviewed Published Clinical Study

    02 Mar 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20220302005311/en

    BUSINESSWIRE
    02 Mar 2022
    Share Share
    ChromaDex Announces Results of New Pilot Clinical Trial of NR Supplementation
    ChromaDex Announces Results of New Pilot Clinical Trial of NR Supplementation

    25 Jan 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20220125005438/en

    BUSINESSWIRE
    25 Jan 2022
    Share Share
    ChromaDex and Designs for Health Partner for New Product Development on Niagen
    ChromaDex and Designs for Health Partner for New Product Development on Niagen

    20 Jan 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20220120005167/en

    BUSINESSWIRE
    20 Jan 2022
    Share Share